Germany makes case for inward investment by US biotech companies

8 April 2010

German foreign trade and inward investment group Germany Trade & Invest (GT&I) had representatives at this year's BayBio 2010 conference held on April 7 in San Francisco, California, USA, to highlight opportunities for American companies in Germany, which is the world's second largest market for biotechnology after the USA.

There are more companies operating in the biotech and biomedical sectors there than in any other country in Europe. Revenue in this industry has grown over 40% between 2005 and 2009 and promises to expand in the coming years.

Eastern German "hot bed" for biotech

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >